Evaluate epidemiologic burden, treatment patterns and treatment outcomes of advanced prostate cancer in Hong Kong using territory-wide electronic medical records
- 1University of Hong Kong
Abstract
BackgroundProstate cancer (PCa) is the most common urological malignancy globally and remains a major cause of cancer mortality among men. In Hong Kong, a comprehensive evaluation of disease burden, real-world treatment patterns, and outcomes across clinically relevant PCa subgroups is essential for identifying unmet needs and optimising care delivery.
ObjectivesThis study aims to characterise the burden of PCa and patterns of care in Hong Kong by (1) estimating annual patient load (2) describing treatment patterns, and (3) evaluating real-world outcomes among patients receiving systemic therapy (chemotherapy or novel hormonal agents [NHA]) and novel agents (immunotherapy, poly ADP-ribose polymerase [PARP] inhibitors, radiation therapy).
MethodsWe conducted a population-based retrospective cohort study using electronic medical records from the Hong Kong Hospital Authority (HA). The cohort included patients diagnosed with PCa between January 1, 2012 and December 31, 2024. Subgroup analyses included patients with metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC) and were further stratified by the treatment received. Descriptive analyses summarised annual patient load and treatment patterns over 2018-2022. We evaluated treatment outcomes from 2012 to 2024, including overall survival, progression-free survival, number of hospitalisations, and main adverse events.
ResultsFrom 2018 to 2022, prevalence increased for prostate cancer (12,014 to 15,610), mHSPC (1,188 to 1,779), and mCRPC (167 to 290), while annual mCRPC incidence rose from 125 to 274. There was an increasing number of prevalent and new users of the investigated novel treatment, including first-/second-/third-line therapy for mCRPC. Compared with patients treated with NHAs, chemotherapy showed a numerically higher rate of hospitalisations, bone treatment initiation and higher hematologic toxicity.
ConclusionsThis population-based retrospective study provides Hong Kong-specific evidence on PCa burden, real-world management, and outcomes across key subgroups, thereby supporting policy planning, formulary evaluation, and targeted strategies to address unmet clinical needs.
FundingThis work was supported by a grant from Novartis.
Related
- Epidemiologic shifts predict spatial patterns of measles re-emergence in the United States
- How Endpoint Definitions Shape Epidemiologic Inference on Tuberculosis Treatment Outcomes: A Secondary Analysis from Lima, Peru.
- Search for the glycated hemoglobin target minimizing mortality among people with type 2 diabetes with rare incidence of treatment-related severe hypoglycemia – Epidemiologic analysis of J-DOIT3 randomized controlled trial
- Multicentre randomised controlled trial to evaluate the efficacy of DIALIVE 2.0, a liver dialysis device, for the treatment of acute-on-chronic liver failure: study protocol
- Proof-of-concept phase II study protocol to evaluate the efficacy and safety of prednisone in the treatment of idiosyncratic hepatotoxicity and its mechanistic pathways through an integrative analysis: the DILICORT clinical trial
BibTeX
@misc{li2026evaluate,
title = {{Evaluate epidemiologic burden, treatment patterns and treatment outcomes of advanced prostate cancer in Hong Kong using territory-wide electronic medical records}},
author = {X. Li and Y. Jiao and J. Wang},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.12.26365031},
url = {https://www.medrxiv.org/content/10.64898/2026.10.12.26365031v1},
note = {CC BY-ND},
}
RIS
TY - UNPB
TI - Evaluate epidemiologic burden, treatment patterns and treatment outcomes of advanced prostate cancer in Hong Kong using territory-wide electronic medical records
AU - X. Li
AU - Y. Jiao
AU - J. Wang
PY - 2026
DA - 2026/10/12
PB - medRxiv
DO - 10.64898/2026.10.12.26365031
UR - https://www.medrxiv.org/content/10.64898/2026.10.12.26365031v1
AB - BackgroundProstate cancer (PCa) is the most common urological malignancy globally and remains a major cause of cancer mortality among men. In Hong Kong, a comprehensive evaluation of disease burden, real-world treatment patterns, and outcomes across clinically relevant PCa subgroups is essential for identifying unmet needs and optimising care delivery. ObjectivesThis study aims to characterise the burden of PCa and patterns of care in Hong Kong by (1) estimating annual patient load (2) describing treatment patterns, and (3) evaluating real-world outcomes among patients receiving systemic therapy (chemotherapy or novel hormonal agents [NHA]) and novel agents (immunotherapy, poly ADP-ribose polymerase [PARP] inhibitors, radiation therapy). MethodsWe conducted a population-based retrospective cohort study using electronic medical records from the Hong Kong Hospital Authority (HA). The cohort included patients diagnosed with PCa between January 1, 2012 and December 31, 2024. Subgroup analyses included patients with metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC) and were further stratified by the treatment received. Descriptive analyses summarised annual patient load and treatment patterns over 2018-2022. We evaluated treatment outcomes from 2012 to 2024, including overall survival, progression-free survival, number of hospitalisations, and main adverse events. ResultsFrom 2018 to 2022, prevalence increased for prostate cancer (12,014 to 15,610), mHSPC (1,188 to 1,779), and mCRPC (167 to 290), while annual mCRPC incidence rose from 125 to 274. There was an increasing number of prevalent and new users of the investigated novel treatment, including first-/second-/third-line therapy for mCRPC. Compared with patients treated with NHAs, chemotherapy showed a numerically higher rate of hospitalisations, bone treatment initiation and higher hematologic toxicity. ConclusionsThis population-based retrospective study provides Hong Kong-specific evidence on PCa burden, real-world management, and outcomes across key subgroups, thereby supporting policy planning, formulary evaluation, and targeted strategies to address unmet clinical needs. FundingThis work was supported by a grant from Novartis.
ER -